SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

WuXi XDC licenses WuXiTecan-2 ADC payload to Ona Therapeutics

WuXi XDC granted Ona Therapeutics an exclusive global license to its WuXiTecan-2 payload, including an upfront, milestone payments, and tiered royalties, plus CMC development and manufacturing support.

2268

WuXi XDC granted Ona Therapeutics an exclusive global license to its WuXiTecan-2 payload—linker for one ADC target, with upfront, milestone payments, and tiered royalties. WuXi XDC will also provide CMC development and manufacturing support.Material DetailsContext by AI AnalystThis extends WuXi XDC…

Related stories